Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs J M Smucker Co (SJM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs J M Smucker Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while J M Smucker Co trades at $111.64 (market cap $11.93B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.3× J M Smucker Co's market cap, and J M Smucker Co pays a 3.94% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SJM | |
|---|---|---|
Market Cap | $39.89B | $11.93B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $117.05 |
52-Week Low | $278.09 | $89.53 |
Enterprise Value | $38.15B | $18.96B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SJM trades at $111.60, up 0.66% today, with technical indicators showing a bearish bias despite recent earnings beats. The company reported a net loss of $1.23 billion in 2025, though revenue grew to $8.73 billion. Analyst consensus is bullish with a $122.92 price target, but weak profitability metrics and high debt levels pose challenges. Recent news highlights mixed sentiment, with some outlets praising growth potential while others caution on sales pressure.
The outlook hinges on margin recovery in coffee and growth in Uncrustables, but fiscal 2027 sales guidance of a 3-4% decline tempers optimism. Risks include competitive pressures and debt management, while the 4% dividend yield offers income support. Upside depends on execution against muted growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
